WASHINGTON — President Trump’s tariffs on prescription drugs coming from the European Union will likely be set at 15% and won’t go into impact till a nationwide safety investigation has been accomplished, based on a White Home official conversant in the plans.
As soon as the Part 232 investigation is completed and its related tariffs are levied, they are going to stay at 15% for the E.U., the particular person stated. They famous that the construction and implementation particulars stay unknown. The Part 232 investigation, which goals to know the nationwide safety implications of counting on different nations for key imports, is ongoing, and it might yield greater tariffs for non-E.U. nations.
The brand new particulars come as a part of a commerce settlement between the U.S. and E.U. reached over the weekend. After the settlement, Trump and European Fee President Ursula von der Leyen appeared to disagree on the deal’s particulars on prescription drugs, the biggest European export to the U.S. Trump stated the settlement didn’t embody prescription drugs, whereas von der Leyen maintained it did.
This text is unique to STAT+ subscribers
Unlock this text — plus day by day protection and evaluation of the pharma business — by subscribing to STAT+.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
